Literature DB >> 17726852

Canine immune-mediated hemolytic anemia: treatment and prognosis.

Andrea Balch1, Andrew Mackin.   

Abstract

The treatment of primary immune-mediated hemolytic anemia involves short-term oxygen-carrying support and long-term immunosuppressive therapy. Therapeutic options include blood transfusion, standard and more speculative immunosuppressive agents, splenectomy, and prevention of thromboembolic disease. This article also discusses the prognosis and prognostic indicators.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17726852

Source DB:  PubMed          Journal:  Compend Contin Educ Vet        ISSN： 1940-8307


  3 in total

1.  In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.

Authors:  Laura A Nafe; John R Dodam; Carol R Reinero
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Diagnostic utility of thoracic radiographs and abdominal ultrasound in canine immune-mediated hemolytic anemia.

Authors:  Michael Andres; Erik Hostnik; Eric Green; Catherine Langston; Valerie J Parker; Chen Gilor; Adam J Rudinsky
Journal:  Can Vet J       Date:  2019-10       Impact factor: 1.008

3.  Gingival overgrowth in a dog that received long-term cyclosporine for immune-mediated hemolytic anemia.

Authors:  Kazuhiko Namikawa; Takuya Maruo; Mayumi Honda; Hitomi Hirata; Jonathan Lynch; Hiroo Madarame
Journal:  Can Vet J       Date:  2012-01       Impact factor: 1.008
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.